GLP-1 & Incretin Science

Berobenatide: The Monthly GLP-1 Candidate

UKPWritten and published by UK Peptides4 min readUpdated 4 cited sources

The short answer

Berobenatide is an investigational GLP-1 receptor agonist developed by Pfizer, previously MET-097i at Metsera. Its sponsor describes it as fully biased and ultra long-acting, and it is being developed for once-monthly maintenance dosing after an initial weekly titration. It is not licensed anywhere.

Key facts

INN
Berobenatide
Development codes
PF-08653944, PF'3944, formerly MET-097 / MET-097i
Class
GLP-1 receptor agonist
Sponsor description
Fully-biased, ultra long-acting GLP-1RA
Route
Subcutaneous injection
Schedule under test
Weekly titration, then monthly maintenance
Highest phase
3 (VESPER-4, NCT07311850)
Regulatory status
Investigational; not licensed in any jurisdiction

Where the description comes from

The phrase used to describe this molecule comes from the sponsor, not from a journalist. The official title of VESPER-4, as registered, reads: 'Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity.' That is the sponsor's own description in a registered protocol title. It tells you what the molecule was designed to be. It does not, on its own, tell you that the design succeeded, and a registered title is not peer-reviewed evidence of receptor pharmacology.

What 'fully biased' is claiming

A GLP-1 receptor does two broadly separable things after an agonist binds: it couples to G proteins, raising cyclic AMP, and it recruits beta-arrestin, which contributes to receptor internalisation and desensitisation. An agonist that engages the first pathway strongly while recruiting little beta-arrestin is called G-protein biased. The rationale is that reduced internalisation leaves more receptor at the surface for longer, so signalling is sustained rather than blunted by desensitisation. Applied to a molecule intended for monthly dosing, that matters more than usual: a drug that has to hold an effect for four weeks between injections cannot afford to be desensitising its own target.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the clinical data actually shows

VESPER-3 (NCT06973720) randomised 268 participants to one of four regimens of twelve weekly doses, with or without titration, followed by monthly doses, or to placebo on the same schedule. The primary endpoint was percent change in body weight at week 28. Reported topline gave placebo-adjusted weight loss of up to 12.3% on the efficacy estimand with a 4.8 mg monthly dose, and 10.5% for that arm on the treatment-policy estimand; another arm reported 10% and 8.4% on the same pair. Separately, VESPER-1's Part B extension reported 15.9% mean weight loss at 32 weeks on the top weekly dose, which is not placebo-adjusted and is not comparable with the figures above.

The tolerability question monthly dosing raises

Weekly incretin dosing lets clinicians titrate slowly, because the interval between dose increases is short. A monthly schedule cannot titrate the same way, and a monthly injection cannot be un-given if it is poorly tolerated. That is why the VESPER-3 design puts twelve weekly doses in front of the monthly phase: the titration happens on the weekly schedule, and the monthly dose is only reached once tolerance is established. Reported gastrointestinal events were predominantly mild to moderate, with no more than one instance of severe nausea or vomiting and no severe diarrhoea reported across the two arms described in the February 2026 topline. Discontinuation for adverse events was five participants during the weekly phase and five during the monthly phase across those arms combined, against zero in placebo.

How it compares with what is licensed

It does not, yet, in any meaningful sense. Semaglutide and tirzepatide have pivotal Phase 3 programmes, cardiovascular outcome data in the case of semaglutide, and years of post-marketing exposure. Berobenatide has Phase 2b data in a few hundred people and Phase 3 trials whose first primary completion is September 2027. A placebo-adjusted 12.3% at week 28 in 268 people is an encouraging Phase 2b result; it is not evidence that can be lined up against a licensed medicine's label.

What this means for anyone reading about it here

Berobenatide is an investigational compound. It is not licensed, not approved, and not supplied on this site in any form. It is covered because the engineering question behind it (whether a GLP-1 effect can be held for a month) is the most interesting unsolved problem in the class, and because the compound has had three names in two years, which makes it unusually easy to misattribute data to.

Quick reference

BerobenatideSemaglutide 2.4 mgTirzepatide
ClassGLP-1 RAGLP-1 RAGIP / GLP-1 dual agonist
Maintenance interval under testMonthlyWeeklyWeekly
Highest phase3, ongoingLicensedLicensed
Pivotal weight dataNone yetYesYes
Cardiovascular outcome dataNoneYesIn progress

Frequently asked questions

Is berobenatide better than semaglutide?

There is no trial that answers that question. No head-to-head comparison has been registered, and comparing a Phase 2b placebo-adjusted figure at week 28 with a Phase 3 result at week 68 in a different population under a different estimand produces a number that means nothing. The honest position is that the comparison has not been made.

Why would monthly dosing matter if weekly already works?

Because adherence to injectable therapy falls over time, and the practical burden of a treatment is part of whether it works in the real world rather than in a trial. That is an argument for testing monthly dosing, not evidence that it delivers, which is what the Phase 3 programme is for.

What does 'ultra long-acting' mean numerically?

The sponsor has not published a half-life for berobenatide in the sources reviewed here. The related amylin analogue PF-08653945 has a reported 19-day observed half-life from Phase 1, which is the kind of duration a monthly schedule requires. Applying that figure to berobenatide would be an assumption, not a fact.

Can I buy berobenatide?

No. It is investigational and not supplied on this site. It has no CAS registration in wide circulation and no established reference material, which means anything offered under the name could not be verified against a standard even in principle.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.